Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660649 | 0.86 | KDM4E (0.57) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL6643616 | 0.83 | KDM4E (0.52) | KDM4EHPGDMAPTSMN1; SMN2CCR6 | |
| SCHEMBL6639297 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL6643288 | 0.80 | KDM4E (0.49) | KDM4EMAPTSMN1; SMN2HTTCCR6 | |
| SCHEMBL6643141 | 0.78 | KDM4E (0.48) | KDM4EMAPTSMN1; SMN2CCR6MEN1 | |
| SCHEMBL2875528 | 0.78 | CRHR1 (0.55) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL29555308 | 0.78 | CRHR1 (0.55) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL6641024 | 0.77 | HTR1B (0.50) | KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL30401658 | 0.77 | CRHR1 (0.53) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL29015162 | 0.77 | CRHR1 (0.53) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-8252793-B2 | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2012024419-A2 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | KDM4E 3092/4885ALDH1A1 3886/4885HPGD 154/4885 |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | KDM4E 3092/4885ALDH1A1 3886/4885HPGD 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.